NeoPhore is a spin out from PhoreMost Ltd which is based at Babraham Research Campus, Cambridge. I hope that isn't how Phoremost isolate themselves from phylogica and their deal when they find something useful. I know always seeing the negative lol. Seems the original deal was
"Under the agreement, Phylogica grants to PhoreMost a world-wide non-exclusive license to use certain Phylomer libraries solely for phenotypic screening to identify novel targets involved in diseases such as cancer, and then to identify and develop small molecule drugs against these targets.
The license includes certain preference conditions that cap the number of similar phenotypic deals Phylogica may enter into during an 18 month option period. Importantly, Phylogica will retain all commercial rights to exploit any Phylomer peptides identified in the screens for therapeutic purposes. " Apr 07, 2015
Maybe the 18 month option period expired
PYC Price at posting:
4.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)